Abstract
The receptor for the lipid mediator PAF (PAFR) is a G-protein coupled receptor expressed in several cell types. Besides PAF, a series of oxidized phospholipids can also bind to PAFR. Dying cells also express PAFR-ligands and, in both situations, scavenger receptors are involved as well. There is evidence that the scavenger receptor CD36 and PAFR associate in the macrophages membrane and signal in conjunction to induce a regulatory phenotype. In the tumor microenvironment, apoptotic cells are abundant due to hypoxia, and PAF-like phospholipids are generated. Engagement of PAFR expressed by tumor macrophages and dendritic cells induces a regulatory/tolerogenic phenotype and subverts the innate and adaptive immune response to the tumor. During cancer therapies, PAFR-ligands can be generated, further aggravating the immune suppression. Moreover, some tumor cells express PAFR and its activation by PAFR-ligands generated during chemotherapy induce anti-apoptotic factors, which protect the tumor cells from death induced by these treatments. It is proposed that PAFR antagonists, administered in combination with chemotherapy, may represent a promising strategy for cancer treatment.
Keywords: Chemotherapy, PAF receptor, tumor growth, tumor macrophages, tumor microenvironment.
Current Drug Targets
Title:PAF Receptor and Tumor Growth
Volume: 15 Issue: 10
Author(s): Sonia Jancar and Roger Chammas
Affiliation:
Keywords: Chemotherapy, PAF receptor, tumor growth, tumor macrophages, tumor microenvironment.
Abstract: The receptor for the lipid mediator PAF (PAFR) is a G-protein coupled receptor expressed in several cell types. Besides PAF, a series of oxidized phospholipids can also bind to PAFR. Dying cells also express PAFR-ligands and, in both situations, scavenger receptors are involved as well. There is evidence that the scavenger receptor CD36 and PAFR associate in the macrophages membrane and signal in conjunction to induce a regulatory phenotype. In the tumor microenvironment, apoptotic cells are abundant due to hypoxia, and PAF-like phospholipids are generated. Engagement of PAFR expressed by tumor macrophages and dendritic cells induces a regulatory/tolerogenic phenotype and subverts the innate and adaptive immune response to the tumor. During cancer therapies, PAFR-ligands can be generated, further aggravating the immune suppression. Moreover, some tumor cells express PAFR and its activation by PAFR-ligands generated during chemotherapy induce anti-apoptotic factors, which protect the tumor cells from death induced by these treatments. It is proposed that PAFR antagonists, administered in combination with chemotherapy, may represent a promising strategy for cancer treatment.
Export Options
About this article
Cite this article as:
Jancar Sonia and Chammas Roger, PAF Receptor and Tumor Growth, Current Drug Targets 2014; 15 (10) . https://dx.doi.org/10.2174/1389450115666140903111812
DOI https://dx.doi.org/10.2174/1389450115666140903111812 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Adipose Stem Cells and Skin Repair
Current Stem Cell Research & Therapy Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry The Role of Circulating Endothelial Progenitor Cells in Tumor Angiogenesis
Current Stem Cell Research & Therapy Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Relationship with Programmed Cell Death Ligand 1 (PD-L1) and DTI Features in Brain Metastases of Non-small Cell Lung Cancer: A Preliminary Study
Current Medical Imaging Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Targeting DNA Associated Processes for Cancer Therapy by the Use of SELEX and Anti-gene Approaches - When Selection Meets Rational Design
Medicinal Chemistry Reviews - Online (Discontinued) Medications Affecting Functional Status in Older Persons
Current Pharmaceutical Design Potential Clinical Applications of (-), (+) and (±)-Z-Bisdehydrodoisynolic Acids in Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Transforming Growth Factor-β: A Molecular Target for the Future Therapy of Glioblastoma
Current Pharmaceutical Design Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance
Current Medicinal Chemistry